A recent study confirmed Genital herpes (GH) is a common sexually transmitted disease associated with adverse health outcomes, which can now be measured in lifetime quality-adjusted life years lost (QALYs).
Published by The Lancet Regional Health Americas on February 7, 2023, this study calculated the average QALYs in the United States is about 18 days of life for one person.
The average number of QALYs lost per GH infection for people aged 18–49 years due to genital HSV-1 and HSV-2 was 0.01 (95% UI 0.01–0.02) and 0.05 (95% UI 0.02–0.09), respectively.

A many-decade leader in polio vaccinations recently issued a foreboding warning that if the U.S. government begins to search for poliovirus in wastewater systems, it may find this harmful virus.
Beyond the Noise is written by Paul Offit, M.D., an infectious diseases physician, author, U.S. FDA vaccine committee advisor, new grandfather, and co-inventor of the rotavirus vaccine.

A recently published Original Article reported positive news regarding the First-in-Human clinical trials assessing Pritelivir, a Nonnucleoside Helicase-Primase Inhibitor targeting the Herpes Simplex Virus (HSV).
As an active ingredient in a new chemical class (thiazolylamides), Pritelivir is active against both types of herpes, HSV-1 and HSV-2.
Published on March 1, 2023, a peer-reviewed study disclosed Pritelivir was evaluated in five phase 1 trials, a single-ascending-dose trial, two multiple-ascending-dose trials, and others.

As the new tetravalent dengue fever vaccine from Takeda Pharmaceutical Company rapidly gains approvals around the globe, many interested parties were asking what this innovative disease protection would cost.
'We aim to make QDENGA® available to all eligible for vaccination in the countries where approved,' stated Takeda's presentation led by Ramona Sequeira, President, Global Portfolio Division, on March 15, 2023.
For example, Takeda disclosed these classifications:

New Tuberculosis (TB) incidence data released today by the U.S. Centers for Disease Control and Prevention (CDC) indicate that TB cases increased by 5% in 2022, impacting about 8,300 patients.
The states of California (1,843) and Texas (1,089) reported the most TB patients last year, led by Dallas and Houston.

Thousands of people living in the State of Kentucky and around the U.S. have been calmly waiting about three weeks for new news regarding measles patients in 2023.
These apprehensive people included over ten thousand school students near Louisville and about twenty thousand college-aged adults who recently attended an event southwest of Lexington.

Just as New Yorkers are finalizing their Spring Break plans, Rockland County Executive Ed Day announced he is urging residents planning to visit countries where poliovirus is found to get a polio booster shot.
According to Rockland County's March 17, 2023, press release, these countries include Israel, the United Kingdom, Ukraine, Afghanistan, Pakistan, Indonesia, Nigeria, Côte d'Ivoire, and several other African countries.

Former NBA superstar Earvin "Magic" Johnson recently agreed to assist in launching Sideline RSV, a new health education campaign aimed to help older adults and their loved ones better understand the risks and potential seriousness of Respiratory Syncytial Virus (RSV) infection.
The new campaign will help bring the RSV conversation to center court as older adults are more likely to have severe outcomes from RSV because the immune system typically weakens as people age.

A novel antiviral may soon become available to treat dengue infections, which impacts millions of people and is threatening people in south Florida and Puerto Rico in 2023.
While two dengue vaccines are authorized in certain countries, no antiviral is commercially available. 

The defense against a mosquito-borne viral disease that has spread to over 125 countries and is one of the World Health Organization's top threats to global health expanded today in Brazil.
An innovative Dengue vaccine that does not require pre-vaccination testing was approved by the National Health Surveillance Agency (ANVISA) to prevent dengue in Brazil caused by any of the four virus serotypes.